BCDA BioCardia
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.
Company profile
Ticker
BCDA, BCDAW
Exchange
Website
CEO
Peter Altman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...
Former names
Cardo Medical, Inc., CLICKNSETTLE COM INC, NAM CORP, Tiger X Medical, Inc.
SEC CIK
Corporate docs
IRS number
232753988
BCDA stock data
()
News
63 Biggest Movers From Yesterday
18 Mar 21
12 Health Care Stocks Moving In Wednesday's Intraday Session
17 Mar 21
BioCardia Says Signs Agreement With 'Leading Japanese Pharmaceutical Company' For Catheter Biotherapeutic Delivery Product Candidates
23 Feb 21
BioCardia Update on Cell Therapy Product Development And 2021 Milestones
2 Feb 21
BioCardia Update on Cell Therapy Product Development And 2021 Milestones
2 Feb 21
Investment data
Securities sold
Number of investors
Calendar
30 Mar 21
13 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from BioCardia earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 21.41M | 21.41M | 21.41M | 21.41M | 21.41M | 21.41M |
| Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 1.17M | 1.29M | 1.14M | 1.03M |
| Cash used (since last report) | n/a | n/a | 4.01M | 4.45M | 3.92M | 3.54M |
| Cash remaining | n/a | n/a | 17.39M | 16.95M | 17.49M | 17.86M |
| Runway (months of cash) | n/a | n/a | 14.9 | 13.1 | 15.4 | 17.3 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar 21 | Moyes Jay M | Common Stock | Grant | Aquire A | No | No | 0 | 3,456 | 0 | 54,267 |
| 31 Mar 21 | Allen Jim L. | Common Stock | Grant | Aquire A | No | No | 0 | 2,520 | 0 | 681,722 |
| 31 Mar 21 | Stertzer Simon H | Common Stock | Grant | Aquire A | No | No | 0 | 2,304 | 0 | 203,554 |
| 31 Mar 21 | Blank Andrew Scott | Common Stock | Grant | Aquire A | No | No | 0 | 4,752 | 0 | 147,192 |
| 31 Mar 21 | Krasno Richard M | Common Stock | Grant | Aquire A | No | No | 0 | 3,024 | 0 | 47,187 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 0 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|
Financial report summary
?Competition
Abbott Laboratories • Caladrius Biosciences • ThermoGenesis • Vericel • Plus Therapeutics • Capricor Therapeutics • Mesoblast • Athersys • VistaGen Therapeutics • uniQureContent analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
adipose, ahead, air, al, alter, alveoli, annum, answered, asymptomatic, bank, Biden, bloodstream, BSC, BSLF, cal, Cap, captioned, cartilage, carve, CCPA, Chhabria, combat, contingent, counter, cybersecurity, Dec, Diego, disagreement, disbursed, disbursement, elastic, energy, EUA, EXXclaim, factor, fat, feasibility, Flexibility, float, fluid, forgivable, forgiven, franchise, Funder, GDPR, genetic, genomic, ground, hand, hierarchical, hypoxemic, illegally, impeded, infection, inflammation, infusion, intravenously, Judge, Krisztina, LDT, Lender, lift, lifted, Lincoln, loan, LPC, MACCE, magnitude, mediator, migrate, moved, multipotent, mutate, nonhierarchical, onset, outreach, oxygen, Park, Paycheck, payroll, PKF, placement, plaintiff, PPP, precipitating, pro, proceeding, proliferation, prolonged, pulmonary, rata, reassigned, repay, rescission, resumed, resuming, risky, rulemaking, sensitive, Silicon, speculative, stroke, stromal, superseded, symptom, syndrome, tiny, trail, transmit, transseptal, unaudited, unbilled, unsecured, Valley, ventilatory, Vincent, vital, workforce, Zsebo
Removed:
adaptation, aim, Allan, apparent, bedside, biologically, Black, burdensome, cancer, characterize, College, compensated, computing, conform, connective, copy, customary, de, dead, decade, deficiency, detail, differentiating, dissolution, easily, exchanged, excise, execute, facilitating, Fernandez, Fernando, fewer, field, finally, Georgia, head, highest, incorporating, injured, Integrated, intramyocardial, Jr, liquidate, listing, marker, medium, microcirculatory, modulation, optimized, percent, Pfenniger, predominantly, prepare, preserved, progenitor, realization, recommending, recreate, rendered, rental, reparative, reservoir, retrospectively, scenario, securely, signaling, sized, sourced, Stanford, surface, Tessler, transplanted, Trump, unearned, unrealized, vasculature, version, vessel, wall, Washington
Financial reports
10-K
2020 FY
Annual report
30 Mar 21
10-Q
2020 Q3
Quarterly report
10 Nov 20
10-Q
2020 Q2
Quarterly report
13 Aug 20
10-Q
2020 Q1
Quarterly report
15 May 20
10-K
2019 FY
Annual report
9 Apr 20
NT 10-K
Notice of late annual filing
31 Mar 20
10-Q
2019 Q3
Quarterly report
19 Nov 19
NT 10-Q
Notice of late quarterly filing
15 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
15 May 19
Current reports
8-K
Other Events
30 Mar 21
8-K
Biocardia Reports 2020 Financial Results and Recent Business Highlights
30 Mar 21
8-K
Entry into a Material Definitive Agreement
29 Mar 21
8-K
Biocardia Signs Agreement with Leading Japanese Pharmaceutical Company for Catheter Biotherapeutic Delivery Product Candidates
23 Feb 21
8-K
Biocardia Announces Clinical Leadership Changes
17 Feb 21
8-K
BioCardia Update on Cell Therapy Product Development and 2021 Milestones
2 Feb 21
8-K
Accomplished Biotech Executive Krisztina Zsebo, PH.D. Joins Biocardia’s Board of Directors
11 Jan 21
8-K
Submission of Matters to a Vote of Security Holders
28 Dec 20
8-K/A
Biocardia, Inc. Announces $10.5 Million
21 Dec 20
8-K
Biocardia Announces Positive DSMB Futility Analysis Review and Recommendation to Continue Phase Iii
17 Dec 20
Registration and prospectus
S-8
Registration of securities for employees
30 Mar 21
424B5
Prospectus supplement for primary offering
29 Mar 21
424B5
Prospectus supplement for primary offering
16 Dec 20
424B5
Prospectus supplement for primary offering
15 Dec 20
S-3
Shelf registration
9 Oct 20
424B4
Prospectus supplement with pricing info
18 Jun 20
S-1/A
IPO registration (amended)
15 Jun 20
FWP
Free writing prospectus
8 Jun 20
S-1/A
IPO registration (amended)
22 May 20
POS AM
Prospectus update (post-effective amendment)
19 Apr 20
Proxies
DEF 14A
Definitive proxy
1 Dec 20
PRE 14A
Preliminary proxy
20 Nov 20
DEFA14A
Additional proxy soliciting materials
15 Oct 19
DEF 14A
Definitive proxy
15 Oct 19
PRE 14A
Preliminary proxy
4 Oct 19
DEF 14C
Information statement
16 Apr 19
PRE 14C
Preliminary information
5 Apr 19
DEF 14A
Definitive proxy
27 Apr 18
DEF 14C
Information statement
9 Oct 17
PRE 14C
Preliminary information
25 Sep 17
Other
EFFECT
Notice of effectiveness
21 Oct 20
CORRESP
Correspondence with SEC
18 Oct 20
UPLOAD
Letter from SEC
14 Oct 20
EFFECT
Notice of effectiveness
17 Jun 20
CORRESP
Correspondence with SEC
14 Jun 20
CORRESP
Correspondence with SEC
14 Jun 20
EFFECT
Notice of effectiveness
22 Apr 20
UPLOAD
Letter from SEC
19 Feb 20
UPLOAD
Letter from SEC
16 Dec 19
CORRESP
Correspondence with SEC
4 Dec 19
Ownership
4
BioCardia / KRISZTINA M ZSEBO ownership change
7 Apr 21
4
BioCardia / Andrew Scott Blank ownership change
7 Apr 21
4
BioCardia / RICHARD M KRASNO ownership change
7 Apr 21
4
BioCardia / JAY M MOYES ownership change
7 Apr 21
4
BioCardia / Jim L. Allen ownership change
7 Apr 21
4
BioCardia / SIMON H STERTZER ownership change
7 Apr 21
SC 13G/A
BioCardia / Altium Capital Management ownership change
10 Feb 21
4
BioCardia / KRISZTINA M ZSEBO ownership change
19 Jan 21
3
BioCardia / KRISZTINA M ZSEBO ownership change
19 Jan 21
4
BioCardia / SIMON H STERTZER ownership change
5 Jan 21
Patents
GRANT
Utility
Devices and methods for accessing the vasculature of a patient
28 Dec 20
A steerable guide sheath system adapted for delivery into a patient's vasculature.
APP
Utility
Radial and Trans-endocardial Delivery Catheter
23 Dec 20
A needle-injection catheter includes a catheter body having a distal end, a proximal end, a stiff proximal portion, a flexible distal portion, and a delivery lumen extending therethrough.
GRANT
Utility
Radial and trans-endocardial delivery catheter
21 Sep 20
A needle-injection catheter includes a catheter body having a distal end, a proximal end, a stiff proximal portion, a flexible distal portion, and a delivery lumen extending therethrough.
GRANT
Utility
Drug delivery catheters that attach to tissue and methods for their use
27 Apr 20
A system and method for delivering a drug to a target site within a patient's body.
APP
Utility
Bone Marrow Derived NEUROKININ-1 Receptor Positive (NK1R+) Precursor Cells for Therapeutic Applications
1 Apr 20
The present disclosure provides use of neurokinin 1 receptor (NK1R) as a marker for identifying and/or isolating multipotential cells.